secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0000899923-26-000012
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics Q4 2025 revenue $209.8M, net loss $7.9M; reiterates 2026 guidance
--------------------------------------------------------------------------------

- GAAP net loss $7.9M ($0.08 loss per share); adjusted EPS $0.04.
- Revenue $209.8M roughly flat YoY; hereditary cancer testing volume +9%, GeneSight +9%, prenatal -6%.
- Full-year 2025 revenue $824.5M down 2%; reiterates 2026 revenue guidance $860-880M.
- Adjusted EBITDA $14.3M in Q4; company expects 2026 adjusted EBITDA $37-49M.
- Plans to launch Precise MRD in March 2026, AI-enabled Prolaris in Q2 2026, FirstGene in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992326000012/0000899923-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992326000012/mygn-20260223.htm
  HTML page:      https://secwatch.observer/filing/0000899923-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer